Suchergebnisse - "Colleoni, M"

PubPharm (381)

1

TAPSE/SPAP ratio stratifies mortality risk in mild-to-moderate idiopathic pulmonary fibrosis

enthalten in: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease | 2024

von Sonaglioni, A. | Caminati, A. | Grasso, E. | +4

2

Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer : Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Rusakiewicz, S. | Tyekucheva, S. | Tissot-Renaud, S. | +18

3

Ultralight vector dark matter search using data from the KAGRA O3GK run

enthalten in: arXiv.org | 2024

von The LIGO Scientific Collaboration | the Virgo Collaboration | the KAGRA Collaboration | +1800

4

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

enthalten in: The New England journal of medicine | 2023

von Partridge, A. | Niman, S. | Ruggeri, M. | +138

CommentIn: Cancer Discov. 2023 Jul 7;13(7):1504-1505. - PMID 37199496

5

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Luen, S. | Viale, G. | Nik-Zainal, S. | +35

6

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Geyer, C. | Garber, J. | Gelber, R. | +174

7

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer : original article

enthalten in: Annals of oncology | 28 November 2022

von Geyer, C. | Garber, J. | Gelber, R. | +73

8

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer

enthalten in: Nature communications | 2022

von Filippone, M. | Gaglio, D. | Bonfanti, R. | +25

9

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer : NeoTRIP Michelangelo randomized study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Gianni, L. | Huang, C. | Egle, D. | +17

10

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials

enthalten in: ESMO open | 2021

von Munzone, E. | Pagan, E. | Bagnardi, V. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[39]